Ferrer
Ferrer, officially known as Ferrer Internacional, is a prominent global pharmaceutical and healthcare company headquartered in Spain. Established in 1959, Ferrer has made significant strides in the industry, focusing on the development of innovative solutions in pharmaceuticals, biotechnology, and consumer health. With a strong presence in Europe, Latin America, and Asia, the company is dedicated to improving patient outcomes through its diverse portfolio. Ferrer’s core offerings include prescription medicines, over-the-counter products, and advanced biopharmaceuticals, distinguished by their commitment to quality and innovation. The company has achieved notable recognition for its research-driven approach and has established itself as a key player in the healthcare sector. With a focus on sustainability and social responsibility, Ferrer continues to enhance its market position while striving to meet the evolving needs of patients worldwide.
DitchCarbon Score
How does Ferrer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ferrer's score of 49 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ferrer's reported carbon emissions
In 2023, Ferrer reported total carbon emissions of approximately 72,902,000 kg CO2e, with Scope 1 emissions accounting for about 7,322,000 kg CO2e and Scope 3 emissions contributing approximately 65,580,000 kg CO2e. This marks a reduction from 2022, where total emissions were about 81,436,000 kg CO2e, with Scope 1 at 7,205,000 kg CO2e and Scope 3 at 74,232,000 kg CO2e. Ferrer has set ambitious climate commitments, aiming to achieve carbon neutrality in its direct emissions (Scope 1) by 2030. Additionally, the company plans to offset its direct emissions, which represent about 15% of total emissions, through projects that prevent carbon emissions or utilise nature-based solutions, such as reforestation. For Scope 2 emissions, Ferrer also aims for a 50% reduction by 2030. The company has committed to reducing its absolute Scope 1 and 2 greenhouse gas emissions by 46.2% and Scope 3 emissions by 27.5% by 2030, using 2019 as the base year. Furthermore, Ferrer intends to increase its sourcing of renewable electricity from 95% in 2019 to 100% by 2030, ensuring that 91% of its suppliers by spend covering purchased goods and services will have science-based targets by 2024. Ferrer’s long-term goal includes becoming carbon positive in its direct emissions by 2030 and achieving carbon positivity in its overall emissions by 2050. These initiatives reflect Ferrer's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 8,369,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,970,000 | 0,000,000 | 000,000 | 000,000 | - | - | - |
| Scope 3 | 21,498,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ferrer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
